Trial reportPloS one2020
Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot's acute neuroarthropathy.
Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04893135 (Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes.Journal of neurology · 2026Article
- When Glycaemic Control Comes Too Fast: Treatment-Induced Neuropathy of Diabetes and Charcot Neuro-Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction.Diabetes/metabolism research and reviews · 2026Review
- [Diabetic Charcot neuroarthropathy initially misdiagnosed as rheumatoid arthritis and gout: A case report].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Does Improvement of Glycemic Control Cause Acute Charcot Foot in Patients with Diabetes?Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2025Review
- Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: The pathobiology and therapeutic implications.World journal of diabetes · 2024Article
- Rapid correction of hyperglycemia: A necessity but at what price? A brief report of a patient living with type 1 diabetes.World journal of diabetes · 2023Article
- Impact of Intensive Glycemic Treatment on Diabetes Complications-A Systematic Review.Pharmaceutics · 2023Review
- Trends in the relation between hyperglycemia correction and active Charcot neuroarthropathy: results from the EPICHAR study.BMJ open diabetes research & care · 2022Article
- Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study.Medicina (Kaunas, Lithuania) · 2022Article
- Why the Risk of Developing Neuroarthropathy Is Higher After Simultaneous Kidney and Pancreatic Transplantation Compared to Kidney Transplantation Only: The Role of Euglycemia.Annals of transplantation · 2021Article
- An overview of Charcot's neuroarthropathy.Journal of clinical & translational endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAggressive antidiabetic therapy and rapid glycemic control are associated with diabetic neuropathy. Here we investigated if this is also the case for Charcot neuroarthropathy. RESEARCH DESIGN AND
methodsHbA1c levels and other relevant data were extracted from medical databases of 44 cases of acute Charcot neuroarthropathy.
resultsHbA1c levels significantly declined from 8.25% (67mmol/mol) [7.1%-9.4%](54-79mmol/mol), at -6 months (M-6), to 7.40%(54mmol/mol) [6.70%-8.03%] (50-64 mmol/mol) during the six months preceding the diagnosis of Charcot neuroarthropathy (P <0.001).
conclusionsHbA1c levels significantly declined during the six months preceding the onset of Charcot neuroarthropathy. This decline seems to be a associated factor with the appearance of an active phase of Charcot neuroarthropathy in poorly controlled patients with diabetic sensitive neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.